Effect of Kinetic Control Retraining on Electromyographic Activity of Trunk Muscles in Patients with Lumbosacral Radiculopathy: A Randomized Controlled Trial.

J Musculoskelet Neuronal InteractSep 1, 2026
Clinical ResearchPhysical Medicine & RehabilitationOpen access

Madonna Maher Ezzat, Nahed Ahmed Salem, Sandra Mohamed Ahmed et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of adding kinetic control retraining to conventional physical therapy in 50 patients with lumbosacral radiculopathy. The study found that the intervention group experienced greater reductions in electromyographic activity of erector spinae and multifidus, as well as improved pain and disability scores compared to the control group.

Key findings

  • The study group showed greater reductions in erector spinae and multifidus activity compared to controls.
  • Visual Analog Scale scores improved more in the kinetic control retraining group.
  • Oswestry Disability Index scores decreased significantly in the intervention group.
  • Transversus abdominis activation increased in the study group.

Why it matters

Improving trunk muscle activation and reducing pain and disability in patients with lumbosacral radiculopathy can enhance rehabilitation outcomes. Understanding effective interventions is crucial for optimizing patient care in physical therapy settings.

Source

PubMed · PMID 42675946Free full text on PubMed Central

Published in J Musculoskelet Neuronal Interact. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.